Access in all areas? A round up of developments in market access and health technology assessment: part 7.

IF 1.9 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Journal of comparative effectiveness research Pub Date : 2025-06-01 Epub Date: 2025-04-14 DOI:10.57264/cer-2025-0043

Sreeram V Ramagopalan, Annie Jullien Pannelay

引用次数: 0

Abstract

In this update, we discuss the implementation progress of the Medicare Drug Price Negotiation Program, with particular focus on the second round of negotiations for 15 additional Part D drugs; explore the role of health technology assessment in US commercial health plan decision-making; and examine significant changes to pharmaceutical pricing systems in Germany, where international reference pricing has been eliminated as part of the Medical Research Act.

查看原文本刊更多论文

所有地区都能通行吗？市场准入和卫生技术评估的发展综述：第7部分。

在本期更新中，我们讨论了医疗保险药品价格谈判计划的实施进展，特别关注另外15种D部分药物的第二轮谈判；探讨卫生技术评价在美国商业卫生计划决策中的作用；并审查德国药品定价制度的重大变化，在德国，作为《医学研究法》的一部分，国际参考定价已被取消。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of comparative effectiveness research HEALTH CARE SCIENCES & SERVICES-

CiteScore

3.50

自引率

9.50%

发文量

121

期刊介绍： Journal of Comparative Effectiveness Research provides a rapid-publication platform for debate, and for the presentation of new findings and research methodologies. Through rigorous evaluation and comprehensive coverage, the Journal of Comparative Effectiveness Research provides stakeholders (including patients, clinicians, healthcare purchasers, and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.